ArticleBMJ open2013
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.Molecular neurobiology · 2017Pooled it
- The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.The Journal of nutrition · 2020Trial
- Metabolic syndrome and breast cancer risk: a case-cohort study nested in a multicentre italian cohort.PloS one · 2015Trial
- Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.Frontiers in immunology · 2024Article
- The NOTCH4-GATA4-IRG1 axis as a novel target in early-onset colorectal cancer.Cytokine & growth factor reviews · 2022Review
- A blood DNA methylation biomarker for predicting short-term risk of cardiovascular events.Clinical epigenetics · 2022Article
- Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.Research and practice in thrombosis and haemostasis · 2022Review
- The Role of Fibrinolytic System in Health and Disease.International journal of molecular sciences · 2022Article
- Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis-From Pathophysiology to Therapeutic Implications.International journal of molecular sciences · 2022Review
- Fibrinogen levels in relation to colorectal cancer onset: A nested case-cohort study from the Moli-sani cohort.Frontiers in cardiovascular medicine · 2022Article
- Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.International journal of cancer · 2021Article
- Engineering of biomaterials for tumor modeling.Materials today. Advances · 2020Article
- Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk.International journal of cancer · 2020Article
- PAI-1 5G/5G genotype is an independent risk of intracranial hemorrhage in post-lysis stroke patients.Annals of clinical and translational neurology · 2019Article
- The fibrotic tumor stroma.The Journal of clinical investigation · 2018Review
- Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.Thrombosis journal · 2018Article
- Tumor Budding, uPA, and PAI-1 in Colorectal Cancer: Update of a Prospective Study.Gastroenterology research and practice · 2017Article
- Getting Old through the Blood: Circulating Molecules in Aging and Senescence of Cardiovascular Regenerative Cells.Frontiers in cardiovascular medicine · 2017Review
- Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke.International journal of endocrinology · 2015Article
- Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke.
designNested case-cohort study.
settingThe European Prospective Investigation into Cancer and Nutrition-Italy cohort.
participantsA centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. MAIN OUTCOMES AND MEASURES: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95% CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method.
resultsIndividuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28; 95% CI 1.46 to 3.55; P for trend<0.0012), breast cancer (HR=1.70; 95% CI 1.21 to 2.39; p<0.0055), ACS (HR=2.57; 95% CI 1.75 to 3.77; p<0.001) and ischaemic stroke (HR=2.27; 95% CI 1.28 to 4.03; p<0.0017), after adjustment for sex and age. Additional adjustment for disease-specific confounders, insulin or other metabolic variables did not modify the associations. Risk of colon cancer was stronger for men and for whole and distal colon localisation. Risk for breast cancer was stronger in postmenopausal women.
conclusionsOur data provide the first evidence that elevated levels of PAI-1 are potential risk factors for colorectal and breast cancer and a common pathway for cancer and cardiovascular disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.